Statistical Analysis Planning & Execution

Insource our high-quality biostatistics skills for cost-effective development
Exploristics can provide the statistical content of your study, ensuring quality and timely delivery.

Using our extensive proprietary library of validated algorithms in SAS and R for preparing, analysing and displaying data, our Biostatistics team can implement bespoke analysis pipelines tailored for your study. This allows us to deliver high quality and expedited analyses for final study reporting, interim analyses, SDAC/IDMC/DSMB support and the implementation of CDISC standards. We adapt our support to cover studies from all phases of development and across any therapeutic area.

[Where SDAC refers to the Statistical Data Analysis Centre, IDMC to the International Data Monitoring Committee, DSMB to the Data Safety and Monitoring Board and CDISC to the Clinical Data Interchange Standards]
Statistical Analysis Planning & Execution
Delivering comprehensive SAPs

We can produce a Statistical Analysis Plan (SAP) describing the analysis approach planned for your study. We adhere to ICH E9 and can develop content for all SAP sections, ensuring there is clear alignment between the study objectives and its outputs. This ensures the tables, figures and listings are fit for purpose and the results are communicated effectively.

Statistical Analysis Planning & Execution
Providing analysis and reporting

We can conduct the statistical analysis and reporting of clinical data. We support all aspects of the analysis including the implementation of data standards (e.g., CDISC), participant disposition, patient populations, descriptive statistics, interim and final analyses for efficacy and safety endpoints. We can also produce all the tables, figures and listings and statistical report as well as input into the clinical study report (CSR).

Statistical Analysis Planning & Execution
Producing high quality outputs

We have rigorous and well tested quality control (QC) processes and governance which deliver high quality outputs for our clients. We have extensive experience and technical ability in analysis of non-standard studies and analysis methods. Our deliverables are always on time which means you have the information to make the right decision for your development program when you need it.

Statistical Analysis Planning & Execution
Delivering comprehensive SAPs

We can produce a Statistical Analysis Plan (SAP) describing the analysis approach planned for your study. We adhere to ICH E9 and can develop content for all SAP sections, ensuring there is clear alignment between the study objectives and its outputs. This ensures the tables, figures and listings are fit for purpose and the results are communicated effectively.

Statistical Analysis Planning & Execution
Providing analysis and reporting

We can conduct the statistical analysis and reporting of clinical data. We support all aspects of the analysis including the implementation of data standards (e.g., CDISC), participant disposition, patient populations, descriptive statistics, interim and final analyses for efficacy and safety endpoints. We can also produce all the tables, figures and listings and statistical report as well as input into the clinical study report (CSR).

Statistical Analysis Planning & Execution
Producing high quality outputs

We have rigorous and well tested quality control (QC) processes and governance which deliver high quality outputs for our clients. We have extensive experience and technical ability in analysis of non-standard studies and analysis methods. Our deliverables are always on time which means you have the information to make the right decision for your development program when you need it.

Common questions which can be addressed by our Biostatistics team include:

Interested in understanding more about the end-to-end statistical planning and analysis we offer? Book a meeting with our Biostatistics team to discover how we can support this.

    Learn how KerusCloud helped provide evidence which was used to support raising US$30 million in a subsequent financing round.

    X